Corporate Overview

CORPORATE PROFILE

Helo Corp

We are a technology, wearable device, and data company with an open platform enabling the conversion of wearer data into actionable wearer information. We embed our Life Sensing Technology into our innovative, connected, wearable devices. Our Life Sensing Technology uses state-of-the-art sensors, enhanced signal processing, and algorithms to collect and process specific data from our device wearers. Our database contains extensive multi-ethnic, biometric and vital sign data, which not only informs our in-house development, but also has the potential to develop into a diverse and abundant resource for wellness and health-related data mining, and third-party software application (or App) development. We continuously gather data from our wearers in an effort to build an anonymized database that may enable our partners to determine new insights, identify new trends generated from our wearer data and offer our wearers information-based solutions based on our platform.

Corporate News

Helo Corp.’s Patent Pending Side Sensor Enables Vascular Age Assessment on its Vyvo Life Watch 2

SAN FRANCISCO, CA / ACCESSWIRE / February 10, 2021 / Helo Corp. (OTC:HLOC) (“Helo” or the “Company), a leading developer of wearable wireless devices embedded with Life Sensing TechnologyTM and dedicated to improving wellness worldwide, is pleased to announce that with its latest Vyvo Smart app update, it provides rapid, non-invasive Vascular Age assessment to all Vyvo Life Watch 2 users worldwide.

Vyvo’s patent-pending side sensor captures high-quality fingertip photoplethysmogram (PPG) signals[1] on demand. Accelerated Plethysmography[2] (APG), which uses the second derivative of PPG waveform, is used to analyze the wearer’s arterial stiffness and estimate their Vascular Age. The whole process takes less than a minute.

Figure: Vyvo Life Watch 2 with patent-pending side sensor and APG result displayed on the Vyvo Smart app.

Understanding the health of your cardiovascular system is paramount, because according to the World Health Organization, more people die annually from cardiovascular disease (CVD) than from any other cause, amounting to 17.9 million people or an estimated 31% of all deaths worldwide.

There are many ways to assess your Vascular Age, such as booking an appointment at a clinic where they can have advanced ultrasound technology, which can be used as an early biomarker of CVD and risk. Alternatively,  your doctor may suggest one or more diagnostic tests, such as blood tests, Doppler ultrasound, Cardiac catheterization and angiogram, or other imaging tests. The challenge with CVD is that it is clinically silent (despite ongoing disease progression) so people at risk do not know to visit their doctor or clinic.

 

You’re as old as your arteries, which doesn’t always equal the number of candles on your birthday cake.” according to Harvard Medical School[3]. In young individuals, arteries are more elastic[4], but as we age, our arteries stiffen, and APG has been found to be useful for the estimation of risk of coronary heart disease in the general population[5].

Seán McVeigh, CEO of Helo Corp says that  “APG technology is becoming more mainstream and it is already being used at clinics throughout the US, but so far, nobody has combined non-invasive Vascular Age assessment with the convenience of a wearable device. Our patent-pending side sensor has enabled this feature.  Our users understand that our Life Watch 2 is not a medical device but it can provide a possible early warning and they should seek expert medical advice if they find that their Vascular Age is significantly greater than their chronological age.”

About Helo Corp.

Helo Corp. (OTC:HLOC) is a wellness technology company in the digital health sharing economy using life watches and its proprietary bio-metrics data platform to encourage wellness-centered lifestyles and consumer data empowerment under the Vyvo brand. Our Life Sensing TechnologyTM uses state-of-the-art sensors, enhanced signal processing, and algorithms to collect and process specific bio-parameters for the user and Healthtech market. We incentivize our userbase with Vyvo Utility Tokens to continuously build up our shared bio-bank through self-tracking. Our two-sided data rich platform collects health data from the users, which we analyze and use AI to formulate customized and personalized user reports, user alerts, and NutraPak supplements, and our platform also presents Big Data opportunity for developers, medical research, and diagnostics.

Vyvo Life Watch 2 wearers can upgrade your App using Google Play or Apple’s App Store.

For further information on Vyvo and Helo, please click on the links below:

https://www.vyvo.com and http://www.helocorp.com

Join Vyvo’s Facebook Community https://www.facebook.com/VyvoCorp

Forward-Looking Statement

This news release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as may, “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” potential and similar statements. All statements other than statements of historical fact in this press release are forward-looking statements and involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. These forward-looking statements are based on management’s current expectations, assumptions, estimates and projections about the Company and the industry in which the Company operates, but involve a number of unknown risks and uncertainties. Further information regarding these and other risks is included in the Company’s filings with the OTC Markets and the Securities and Exchange Commission. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and actual results may differ materially from the anticipated results. You are urged to consider these factors carefully in evaluating the forward-looking statements contained herein and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by these cautionary statements.

Investors Contact:

investors@helocorp.com

650-646-2193

ClearThink

nyc@clearthink.capital

[1] Elgendi M. On the analysis of fingertip photoplethysmogram signals. Curr Cardiol Rev. 2012;8(1):14-25. doi:10.2174/157340312801215782.

[2] Takada H, Washino K, Harrell JS, Iwata H. Acceleration plethysmography to evaluate aging effect in cardiovascular system. Using new criteria of four wave patterns. Med Prog Technol. 1996-1997;21(4):205-10. PMID: 9110278.

[3] Ask the doctor: Is it possible to reverse coronary artery disease?

[4] Mikael LR, Paiva AMG, Gomes MM, et al. Vascular Aging and Arterial Stiffness.Arq Bras Cardiol.2017; 109(3):253-258. doi:10.5935/abc.20170091.

[5] Otsuka T, Kawada T, Katsumata M, Ibuki C. Utility of second derivative of the finger photoplethysmogram for the estimation of the risk of coronary heart disease in the general population. Circ J. 2006 Mar;70(3):304-10. doi: 10.1253/circj.70.304. PMID: 16501297.

Helo Corp.’s Vyvo Life Watch Generation 2 Campaign Launch Received a Platinum and Two Gold Awards at the 15th Annual AVA Digital AwardsPress Release | 02/02/2021

SAN FRANCISCO, CA / ACCESSWIRE / February 2, 2021 / Helo Corp. (OTC PINK:HLOC) (“Helo” or the “Company), a leading developer of wearable wireless devices embedded with Life Sensing TechnologyTM and dedicated to improving wellness worldwide, is pleased to announce that Vyvo has received a Platinum and Two Gold awards at the 15th annual AVA Digital Awards.

One of the Vyvo Life Watch videos can be viewed below[1]:

For more detailed information and a complete list of winners honoring web production, digital marketing, digital video creation, pro-bono excellence, administered by the Association of Marketing and Communication Professionals, please visit: https://avaawards.com.

The AVA Awards were awarded for Vyvo’s Life Watch digital campaign launch and had been awarded a Platinum Award for the category of Digital Video Creation, Motion Graphics Product. Vyvo also received two Golds: the first for their Social Campaign in the category of Video Production, Commercials, Product, and the latter in the category of Web-Based Production, Short Form Web Video – under 3 Minutes, Healthcare.

The second award winning video can be viewed below[2]:

“I’m both incredibly honored and proud of what we have accomplished with our launches of life-changing technologies like in our Life Watch Generation 2. The fact that we have continued receiving recognition from peers in the industry, and specifically for how we are sharing the message about the impact our Digital Health Sharing Economy can have, not only serves to affirm that everyone on the Vyvo Journey is on the smart path to success,” commented Vyvo CEO Fabio Galdi.

The collection of accolades that Vyvo has recently received showcases the strength of their message, highlighting that Vyvo’s offering is not just a Life Watch that collects your data; it is a Life Watch that powers an emerging Digital Health Sharing Economy that’s growing quickly and is a first in the direct selling space. Vyvo has been on point in reaching their audiences with compelling and informational content that shows the great potential of their unique and lucrative home-based tech opportunity – catering to every individual’s financial goals and flexibility.

About Helo Corp.
Helo Corp. (OTC PINK:HLOC) is a wellness technology company in the digital health sharing economy using life watches and its proprietary bio-metrics data platform to encourage wellness-centered lifestyles and consumer data empowerment under the Vyvo brand. Our Life Sensing TechnologyTM uses state-of-the-art sensors, enhanced signal processing, and algorithms to collect and process specific bio-parameters for the user and Healthtech market. We incentivize our userbase with Vyvo Utility Tokens to continuously build up our shared bio-bank through self-tracking. Our two-sided data rich platform collects health data from the users which we analyze and use AI to formulate customized and personalized user reports, user alerts and Nutrapak supplements, and our platform also presents Big Data opportunity for developers, medical research, and diagnostics.

For further information on Vyvo and Helo, please click on the links below:

https://www.vyvo.com and http://www.helocorp.com

Join Vyvo’s Facebook Community.https://www.facebook.com/VyvoCorp

Forward-Looking Statement
This news release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as may, “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” potential and similar statements. All statements other than statements of historical fact in this press release are forward-looking statements and involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. These forward-looking statements are based on management’s current expectations, assumptions, estimates and projections about the Company and the industry in which the Company operates, but involve a number of unknown risks and uncertainties. Further information regarding these and other risks is included in the Company’s filings with the OTC Markets and the Securities and Exchange Commission. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and actual results may differ materially from the anticipated results. You are urged to consider these factors carefully in evaluating the forward-looking statements contained herein and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by these cautionary statements.

Investors Contact:
investors@helocorp.com
650-646-2193

ClearThink
nyc@clearthink.capital


[1] This is a New Generation Life Watch video: https://vimeo.com/467696704

[2] Everything Changed When You Came into My Life video: https://vimeo.com/467696704


https://vimeo.com/467696704SOURCE: Helo Corp.

View source version on accesswire.com:
https://www.accesswire.com/627168/Helo-Corps-Vyvo-Life-Watch-Generation-2-Campaign-Launch-Received-a-Platinum-and-Two-Gold-Awards-at-the-15th-Annual-AVA-Digital-Awards

Vyvo Becomes Publicly Traded in a Transaction Valued at $50 Million with Helo Corp.

San Francisco, CA – Accesswire – January 14, 2021 — Helo Corp. (OTC: HLOC) (“Helo” or the “Company), a leading developer of wearable wireless devices embedded with Life Sensing TechnologyTM and dedicated to improving wellness worldwide, is pleased to announce the closing of its acquisition of Vyvo Inc. (“Vyvo”) on January 1, 2021, which transfers the Vyvo business into a publicly traded entity. Vyvo is building a worldwide community of passionate users who leverage technology to live healthier and happier lives with greater prosperity.

The all stock transaction encompasses the issuance by Helo of 50 million common shares, 100 Preferred A Super Voting shares and 2 million Preferred B shares in exchange for Vyvo’s strategic assets, including patents, technologies and operational assets. These assets include Nutramatic, GlucoStrap, Artificial Intelligence(AI) protocols and machine learning processes and Vyvo Network Software. As part of the transaction, $1.8 million of Helo’s debt was forgiven. In addition, Vyvo members who are already shareholders will automatically attain shares in HLOC.

This transaction, effective January 1, 2021 has enabled Helo Corp. to secure all of the technological assets and capabilities necessary to transition from a wholesale device business to a business-to-consumer business model where HLOC secures increased revenues from the sale of its devices (as it captures a greater portion of the value chain) and additional revenues from the sale of other Vyvo products and services.

Sean McVeigh, Helo’s Chief Executive Officer, commented, “This transaction that brings Vyvo public is a major milestone for us and we wish to thank all who made it possible. We look forward to executing on our strategic plan by capitalising on Vyvo’s leading position in the digital health industry, and building shareholder value for our holders, employees, partners and Vyvo members.”

Fabio Galdi, Vyvo’s Chief Executive Office, stated, “Going public has always been part of the Vyvo’s mission and now that we have achieved this important objective, we can bring even more value to Vyvo members who, as shareholders, will continue to promote Vyvo going forward, securing Vyvo’s revenue stream. We will utilize our new public currency as an incentive and retainment tool for our members in order to build shareholder value.”

Vyvo’s established global presence and network marketing approach, combined with social selling enables it to reach consumers worldwide. The Company has 80+ employees in 10 locations, spanning USA, Japan, Taiwan, India, China, Singapore, Thailand, Russia, Italy and Ireland. According to Fabio Galdi, Vyvo’s customer acquisition process is simple and highlights that one of the key revenue drivers is that Vyvo users who are passionate about Vyvo’s product offering and who choose to promote Vyvo to other potential users, receive a commission when the prospect becomes a Vyvo customer by placing an order directly with Vyvo. With this approach, Vyvo has established business in Asia and is preparing its North America launch in the second quarter of 2021.

According to the Deloitte’s video “The Future of Health”, Deloitte states that, “20 years from now, radically interoperable data and open and secure will allow consumers to own their own journey of health.” Click on the icon to view Deloitte’s video[1]:

Fabio Galdi states that “We have the technology and capability so we are not willing to wait until 2040. We are already building many aspects of the “The Future of Health” ecosystem outlined in the Deloitte video. Vyvo users today enjoy features such as Guardian Alert, which can detect changes or deviations in their vital signs so they are alerted and can take immediate action. Our users also benefit from personalized AI generated reports and customized products, based on their data (similar to “precision medicine”). In addition, in this age where individual rights and privacy is being challenged, Vyvo will provide users with their own unique cryptographic key so they are in control of their data. only Vyvo users hold their  own Etherium blockchain private cryptographic key which allows them to be in full control of their data all of the time. With all of these elements in place, we believe that Vyvo has created the first self-funded, “Digital Health Sharing Economy” because we use blockchain technology to share the revenue generated from Digital Health industry, expected to reach US$833 billion by 2027[2] with these users themselves.  We actually pay our users for their data which is automatically gathered when they wear our Vyvo Life Watch!”

For an overview of Vyvo’s LifeWatch Generation 2, please click on the icon[3]:

 https://vimeo.com/469087851

 

About Helo Corp.

Helo Corp. (OTC: HLOC) is a wellness technology company in the digital health sharing economy using life watches and its proprietary bio-metrics data platform to encourage wellness-centered lifestyles and consumer data empowerment. Our Life Sensing TechnologyTM uses state-of-the-art sensors, enhanced signal processing, and algorithms to collect and process specific bio-parameters for the user and Healthtech market. We incentivize our userbase with Vyvo Utility Tokens to continuously build up our shared bio-bank through self-tracking. Our two-sided data rich platform collects health data from the users which we analyze and  use AI to formulate customized and personalized user reports, user alerts and Nutrapak supplements, and our platform also presents Big Data opportunity for developers, medical research, and diagnostics.

For further information on Vyvo and Helo, please click on the links below:

https://www.vyvo.com and http://www.helocorp.com

 

Forward Looking Statement

This news release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as may, “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” potential and similar statements. All statements other than statements of historical fact in this press release are forward-looking statements and involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. These forward-looking statements are based on management’s current expectations, assumptions, estimates and projections about the Company and the industry in which the Company operates, but involve a number of unknown risks and uncertainties. Further information regarding these and other risks is included in the Company’s filings with the OTC Markets and the Securities and Exchange Commission. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and actual results may differ materially from the anticipated results. You are urged to consider these factors carefully in evaluating the forward-looking statements contained herein and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by these cautionary statements.

Investors Contact:

investors@helocorp.com
650-646-2193

ClearThink

nyc@clearthink.capital

[1] https://www2.deloitte.com/global/en/pages/life-sciences-and-healthcare/articles/future-of-health.html

[2] https://www.globenewswire.com/news-release/2020/11/17/2128470/0/en/Digital-Health-Market-Size-to-Hit-Around-US-833-44-bn-by-2027.html

[3] https://vimeo.com/469087851

Helo Corp invites health researchers and medical professionals to join Project CEASE, an international field experiment using AI and anonymized VYVO smartwatch data to identify the onset of COVID-19

May 20, 2020
OTC Disclosure & News Service
San Francisco, CA —

San Francisco, California May 20, 2020 – Helo Corp. (OTC: HLOC) (Helo Corp), a leading developer of wearable devices embedded with Life Sensing TechnologyTM and dedicated to improving wellness worldwide, today invites health researchers and medical professionals to join its Project CEASE (COVID-19 Early Alert System Experiment) to help format and analyze its anonymized VYVO smartwatch wearer data to see if data patterns gathered from its wellness devices can be used to indicate the onset of a viral infection, such as COVID-19.

Helo Corps smartwatch data is already being used in an early alert system called Guardian Alert, which is available to VYVO smartwatch wearers who have pre-selected their guardians for notification if their data indicates that they have fallen or they have had an Atrial Fibrillation episode or a sleep apnea event. In addition, the Guardian Alert system notifies guardians if the wearers breath rate, heart rate, blood oxygenation and temperature are outside of their normal ranges.

Although Helo Corps non-invasive devices are intended only for general wellness use and provide personal tracking as part of promoting a healthy lifestyle, we believe the data that these devices gather will provide useful insights for participants in Project CEASE, both VYVO smartwatch wearers and the health and medical professionals who join us. In addition, Project CEASE data will soon be enhanced with data from VYVOs latest devices which are currently in production and use medical grade sensors for temperature measurement. These sensors provide 0.1C accuracy from 30 to 45C (86 to 113F) and meet the American Society for Testing and Materials (ASTM) E1112 and International Organization for Standardization (ISO) 80601 requirements for patient thermometers.

Helo Corp is asking VYVO smartwatch wearers to share their ongoing bio-data gathered from their VYVO smartwatch and to complete a health status questionnaire, which will includes results from the rapid antibody COVID-19 test kit that is being provided to wearers that participate in Project CEASE. These test kits with two separate tests included, have already been sourced from approved manufacturers and selected for participants depending on the participants location, to ensure compliance with their local country regulations. Test kits are being provided to participants to standardize participants infection status feedback across the project.

Project CEASE is being conducted in three phases. The first phase of data collection will commence when existing VYVO smartwatch wearers opt-in to sharing their bio-data using their VYVO Smart App. The Algorithm Training Phase, the second phase, will commence once sufficient data has been gathered to train our AI algorithm to identify possible data patterns that may indicate the presence of a viral respiratory infection. The third or Validation Phase, is where the trained AI algorithm is applied to Project CEASE participants whose infection status is unknown. If a high probability of an influenza-like infection is detected in a participants data, they will receive an Early Alert notification (similar to the image below). To validate the notification as generated by the AI algorithm, the participant will be requested to consult with their doctor and, if so advised, undertake and share the result of their COVID-19 test.

Simulated Guardian Alert notification image.

Helo Corp believe the collection and aggregation of the bio-data of our smartwatch customers may be beneficial to the broader healthcare community. Consequently, Helo Corp is reaching out to medical doctors, professional researchers, healthcare providers, government bodies, hospitals, universities and commercial entities with project relevant capabilities to join Project CEASE to assist Helo Corp in framing the scope and format of the bio-data that we collect in a way that would be most useful. The broader goal of Project CEASE would be to gather and make available Helo Corps aggregated, anonymized wearer data and Artificial Intelligence (AI) to assist the healthcare community to identify data patterns which might be used by them to indicate the onset of a viral infection, such as COVID-19. This aggregated, anonymized wearer data is available free to all approved research partners while Project CEASE remains active.

Fabio Galdi, CTO and Chairman of Helo Corp, said that To ensure Project CEASE is meaningful on a worldwide scale, we are looking for at least 25,000 VYVO smartwatch wearers to contribute their data. The good news is that we believe we can easily achieve this level of participation with our existing VYVO smartwatch wearers. Using this crowd sourced, cloud based real-time data collection process, together with the power of big data analysis and machine learning, we expect to be able to provide bio-data that will indicate patterns and trends to assist in identifying a likely onset of a viral infection. This would enable us to not only notify the VYVO smartwatch wearer so they can seek early treatment and self-isolate to protect their family and friends but also benefit the healthcare community as a whole. Using traditional research methods, a global field experiment of this magnitude could take years, Mr. Galdi continued but we believe that, by using our devices and technology, we have the potential to see meaningful results and possibly Project CEASE validation in a much shorter time frame.

Sean McVeigh, CEO of Helo Corp., said that, Although today COVID-19 detection is a high priority activity, this type of research and development is not new for us. Our VYVO smartwatches already provide personal alerts and supporting data to wearers and their guardians, when events such as atrial fibrillation, low blood oxygenation, elevated temperature or sleep apnea are detected. However, given the critical nature of this pandemic, our focus is on Project CEASE so we can make our contribution to science by providing readily available and real-time data set that will help identify the mechanism of action of this virus, minimize its impact and reduce transmission rates. We thank our prospective VYVO participants for their invaluable contribution and welcome the opportunity to invite and share our aggregated data with other experts, so we can all do our part to help stop the transmission of this virus.

About Helo Corp.

Helo Corp. is a technology company that provides wearable devices for use in the quantified-self, wellness market. Our wearable devices and related applications provide our wearers with health related knowledge acquired through self-tracking. Our Life Sensing TechnologyTM uses state-of-the-art sensors, enhanced signal processing and algorithms to collect and process specific data gathered from our smartwatch wearers; and it is embedded into our wearable devices that are designed, produced and sold into the wellness market through our marketing and distribution partner, Vyvo Pte. Ltd. and its distribution network. For further information, please see: www.helocorp.com.

Project CEASE is being managed by Vyvo Labs, the Quantified-Self Research Center of Helo Corps US subsidiary, Vyvo Technology Corp. For further information, please see www.vyvolabs.com.

Contact: investors@helocorp.com or +1 650-646-2193

Forward Looking Statement

This news release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as may, “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” potential and similar statements. All statements other than statements of historical fact in this press release are forward-looking statements and involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. These forward-looking statements are based on management’s current expectations, assumptions, estimates and projections about the Company and the industry in which the Company operates, but involve a number of unknown risks and uncertainties. Further information regarding these and other risks is included in the Company’s filings with the OTC Markets and the Securities and Exchange Commission. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and actual results may differ materially from the anticipated results. You are urged to consider these factors carefully in evaluating the forward-looking statements contained herein and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by these cautionary statements.

Helo Corp. Announces Signing of $88M Letter of Intent with Vyvo Inc.

February 3, 2020
OTC Disclosure & News Service
San Francisco, CA —

San Francisco, California February 3, 2020 – Helo Corp. (OTC: HLOC) (the Company), a leading developer of wearable devices embedded with Life Sensing Technology and dedicated to improving wellness worldwide, today announced that it has signed a Letter of Intent with Vyvo Inc. to acquire certain strategic assets from Vyvo Inc. so that it can bring the Vyvo business into a public company.

Sean McVeigh, CEO of Helo Corp., said that, This transaction, which includes the acquisition of assets such as intellectual property, network software, strategic supplier and distribution contracts and debt forgiveness should enable us to quickly transition into the Vyvo business and also improve our balance sheet. We expect that this agreement will significantly increase our sales revenues as we will capture more of the customer transaction value when customers purchase our wearable devices, and we will also secure additional sales revenues from new products and services. Furthermore, the Company should be able to immediately recognize this additional revenue upon closing.

Upon closing, Fabio Galdi will be appointed CEO, Alessandro Senatore will be appointed COO and Sen McVeigh will continue as CFO of Helo Corp. Closing of this transaction is subject to the execution of definitive agreements on acceptable terms and the transfer of $88M HLOC shares to the ultimate beneficial owners of Vyvo Inc., namely Fabio Galdi, Alessandro and Sen McVeigh It is also subject to other customary conditions and is expected to occur no later than 30thApril, 2020. There can be no assurance that the acquisition will be completed in the stipulated time or at all.

Fabio Galdi said, We are extremely excited for the future at Vyvo. As a public company we will have the unique ability to tell our story and access capital in a much more efficient manner. It is an exciting time for us as we will have the technology and expertise all in-house to make a big impact on the $190B worldwide direct selling wellness market. We hope to lead the way in changing how the financial market views direct selling business model by combining our proven technology with Artificial Intelligence (AI) and producing a stream of next generation products that will improve our customers wellness. He continued, We are delighted with this agreement as it allows us to tie in and consolidate all of VYVO’s key activities under one company. The synergies are enormous. From a technology perspective, we can optimise the integration of AI into the Companys Life Sensing Technology so that we can produce more exciting, customized products that will bring significant and tangible wellness benefits to our customers. Also, our members will benefit financially from this agreement. It gives us the ability to open up new markets in USA, Asia, Europe and Russia, which will generate customer referral commissions for our existing and new members. Mr Galdi also confirmed that the Company will continue to operate under the HLOC ticker until it can change its name to Vyvo and update its ticker symbol.

Contact

investors@helocorp.com

+1-650-646-2193

About VYVO Inc.

We are a technology and network marketing company, using technology to create innovative solutions for the personalized health and wellness market worldwide. We are focused on developing consumer-oriented products that protect, monitor and empower people to improve their health through daily knowledge and informed choices. We create customized solutions to help our customers manage their most important asset, themselves and their life.

Our technology driven mission matches our network marketing soul. We are all about expanding concepts of personal growth and development, not only focusing on health but also on prosperity and economic wellbeing. For more information, please see www.vyvo.com.

About Helo Corp.

We are a technology company that provides wearable devices for use in the quantified-self wellness market. Our wearable devices and related applications provide our end-users with health related knowledge acquired through self-tracking. Our Life Sensing Technology uses state-of-the-art sensors, enhanced signal processing and algorithms to collect and process specific data from end-users; and it is embedded into branded wearable devices that are designed, produced and sold into the wellness market through our marketing and distribution partner, Vyvo Pte. Ltd. and its distribution network. For more information, see www.helocorp.com.

Forward Looking Statement

This news release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as may, “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” potential and similar statements. All statements other than statements of historical fact in this press release are forward-looking statements and involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. These forward-looking statements are based on management’s current expectations, assumptions, estimates, and projections about the Company and the industry in which the Company operates, but involve a number of unknown risks and uncertainties. Further information regarding these and other risks is included in the Company’s filings with the OTC Markets and the Securities and Exchange Commission. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and actual results may differ materially from the anticipated results. You are urged to consider these factors carefully in evaluating the forward-looking statements contained herein and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by these cautionary statements.

World Technology Announces Corporate Name Change to Helo Corp.

WCOR Trades Under New Ticker Symbol “HLOC” Effective October 31, 2018

MIAMI, Oct. 31, 2018 (GLOBE NEWSWIRE) — World Technology Corp. (OTC: HLOC) (the “Company”), a leading developer of Helo wearable devices embedded with Life Sensing Technology and dedicated to improving wellness worldwide, announced approval from the Financial Industry Regulatory Authority (“FINRA”) of the Company’s corporate action request changing its name to Helo Corp. FINRA also approved a change of its ticker symbol to “HLOC” with an effective date at the open of the market on October 31, 2018.

About Helo Corp.
We are a technology, wearable device and data company with an open platform enabling the conversion of wearer data into actionable wearer information. We embed our Life Sensing Technology into our innovative, connected, Helo wearable devices. Our Life Sensing Technology uses state-of-the-art sensors, enhanced signal processing and algorithms to collect and process specific data from our device wearers. Our database contains extensive multi-ethnic, biometric and vital sign data that not only informs our in-house development but also has the potential to develop into a diverse and rich resource for wellness and health-related data mining, and third party software application development. We continuously gather data from our wearers in an effort to build an anonymized database that may enable our partners to determine new insights, identify new trends generated from our wearer data and offer our wearers information-based solutions based on our platform.

For further information, see www.helocorp.com

Forward Looking Statement
This news release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “may,” “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “potential” and similar statements. All statements other than statements of historical fact in this press release are forward-looking statements and involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. These forward-looking statements are based on management’s current expectations, assumptions, estimates and projections about the Company and the industry in which the Company operates, but involve a number of unknown risks and uncertainties. Further information regarding these and other risks is included in the Company’s filings with the OTC Markets and the Securities and Exchange Commission. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and actual results may differ materially from the anticipated results. You are urged to consider these factors carefully in evaluating the forward-looking statements contained herein and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by these cautionary statements. 

At the Company:
Sean McVeigh, CEO
Email: investors@helocorp.com
Phone: 305-504-7173

WCOR’s Non-invasive Blood Sugar Trend Monitoring Device Receives CE Class 1 Medical Device Certification

MIAMI, Sept 17, 2018 (GLOBE NEWSWIRE) – World Technology Corp. (OTC: WCOR) (“World Technology” or the “Company”), a technology company that leverages its Life Sensing Technology to promote wellness worldwide using its Helo branded wearable devices, today announced that its Helo Extense device, a portable, stand-alone device that is capable of non-invasively measuring the user’s blood sugar trend conveniently and on demand, has received CE Class 1 Medical Device Certification (the “Certification”) from the Ministry of Health in Italy. The Certification confirms that the Helo Extense device is considered safe and a low-risk device when used as intended.  The Company is in the process of completing certification of Helo Extense’s measurement function and anticipates attaining this certification during the fourth quarter of 2018.

“The Certification is an important milestone for our Company,” commented Sean McVeigh, Chief Executive Officer of World Technology. ”We believe that receipt of the Certification demonstrates our commitment and ability to develop quality products that promote wellness. We believe this Certification, together with certification of Helo Extense’s measurement function will not only enhance the credibility of our Helo products in our current self-monitoring wellness market, but will also pave the way for us to enter the healthcare market, once we secure appropriate approvals.”

“On the strategic front, we believe that we are making progress with our plan to expand our product offerings and revenue base, and we are continuing to pursue an up-listing of our common stock to Nasdaq,” continued Mr. McVeigh.

About World Technology Corp.

We are a technology, wearable device, and data company with an open platform enabling the conversion of wearer data into actionable wearer information. We embed our Life Sensing Technology into our innovative, connected, wearable devices. Our Life Sensing Technology uses state-of-the-art sensors, enhanced signal processing, and algorithms to collect and process specific data from our device wearers. Our database contains extensive multi-ethnic, biometric and vital sign data that not only informs our in-house development but also has the potential to develop into a diverse and rich resource for wellness and health-related data mining and third-party software application development. We continuously gather data from our wearers in an effort to build an anonymized database that may enable our partners to determine new insights, identify new trends generated from our wearer data and offer our wearers information-based solutions based on our platform. For further information, see www.worldcorp.com

Forward-Looking Statement

This news release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “may,” “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “potential” and similar statements. All statements other than statements of historical fact in this press release are forward-looking statements and involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. These forward-looking statements are based on management’s current expectations, assumptions, estimates and projections about the Company and the industry in which the Company operates, but involve a number of unknown risks and uncertainties. Further information regarding these and other risks is included in the Company’s filings with the OTC Markets and the Securities and Exchange Commission. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and actual results may differ materially from the anticipated results. You are urged to consider these factors carefully in evaluating the forward-looking statements contained herein and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by these cautionary statements. 

At the Company:

Sean McVeigh, CEO

Email: investors@worldcorp.com

World Technology Corp. Files Registration Statement on Form S-1

MIAMI, August 6, 2018 (GLOBE NEWSWIRE) – World Technology Corp. (OTC: WCOR) (“World Technology” or the “Company”), a technology company that leverages its Life Sensing Technology to promote wellness worldwide using its Helo branded wearable devices, today announced that it has filed a registration statement on Form S-1 (“S-1”) with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed public offering of shares of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. World Technology has applied to list its common stock on the NASDAQ Capital Market in connection with the proposed offering. Dawson James Securities, Inc. will act as the sole book-running manager for the proposed offering.

These securities may not be sold, nor may offers to buy be accepted, prior to the time the S-1 becomes effective. The proposed public offering will be made only by means of a prospectus. The S-1 has not yet become effective.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Forward-Looking Statement

This news release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “may,” “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “potential” and similar statements. All statements other than statements of historical fact in this press release are forward-looking statements and involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. These forward-looking statements are based on management’s current expectations, assumptions, estimates and projections about the Company and the industry in which the Company operates, but involve a number of unknown risks and uncertainties, Further information regarding these and other risks is included in the Company’s filings with the OTC Markets and the Securities and Exchange Commission. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and actual results may differ materially from the anticipated results. You are urged to consider these factors carefully in evaluating the forward-looking statements contained herein and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by these cautionary statements. 

At the Company:

Sean McVeigh, CEO

Email: investors@worldcorp.com

World Technology Corp. Launches its Non-Invasive Sugar Trend Monitoring Device, Helo Extense

MIAMI, August 6, 2018 (GLOBE NEWSWIRE) – World Technology Corp. (OTC: WCOR)
(“World Technology” or the “Company”), a technology company that leverages its Life Sensing
Technology to promote wellness worldwide using its Helo branded wearable devices, today
announced the commercial launch of Helo Extense, a portable, stand-alone, connected device
that non-invasively and conveniently monitors on demand wearer’s blood sugar trend. The
launch in Singapore on July 28 and 29, 2018 was hosted by World Global Network, WCOR’s
exclusive distributor for the wellness sector.

World Technology Corp. Secures Toshiba Processor for Production of Helo Extense, its non-invasive Sugar Trend Monitoring Device

MIAMI, June 06, 2018 (GLOBE NEWSWIRE) — World Technology Corp. (OTC:WCOR) (“World Technology” or the “Company”), a technology company that leverages its proprietary Life Sensing Technology to promote wellness worldwide using its Helo branded wearable devices, has secured, through its supplier, a high performance, low power Toshiba Processor as one of the main components of Extense – a companion device that allows Helo LX and Helo LX+ wearers worldwide to monitor their sugar trends on demand and on a non-invasive basis.

Sean McVeigh, Chief Executive Officer of World Technology, commented, “Following the launch of Helo LX+ and the demonstration of our non-invasive Sugar Trend monitoring technology at CES 2018 in Las Vegas, we have dedicated substantial resources toward the development of Helo Extense. After careful consideration and extensive planning, we have selected and secured Toshiba’s TZ1200 Processor for use in our non-invasive Sugar Trend monitoring device, Helo Extense.

Mr. McVeigh continued, “We are excited about fast-tracking the production of Helo Extense starting mid-2018 and the related momentum that we expect it will bring to our business in the second half of the year.” He also confirmed that “Helo Extense will only be available for sale in the wellness sector from WCOR’s exclusive distributor, World Global Network.”

More News

Click Here